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S
ince the first evidence of the biocom-
patibility of porous silicon (PSi),1 there
have been a growing number of
publications about its numerous
applications.24 While most of the research
has been focused on microdevices for
therapeutic use,5 chemical and biological
sensors,6 and optoelectronics,7 other appli-
cations have also emerged, such as intrave-
nous8 and ocular drug delivery.9,10 Oral de-
livery still remains the route preferred by
patients and thus dominates controlled re-
lease research.11 Drug and peptide delivery
by PSi particles has already been demon-
strated and with promising results.12,13 PSi
particles can be loaded with diverse pay-
loads, such as small molecule drugs and
peptides. In addition, improved solubility
of poorly soluble drugs after loading has
been reported.1416 The silicon surface can
be treated in the gas phase by oxidation,
hydrosilylation, and thermal carbonization,3
or it can also be grafted with numerous
functional moieties, including polyethyle-
neglycol17 and folate.18 Recently, the suit-
ability of thermally hydrocarbonized silicon
(THCPSi) microparticles for peptide delivery
was demonstrated.19 The stabilization of PSi
with thermal carbonization was used to pre-
vent chemical reactions between the pep-
tide and the PSi surface. Despite the stabil-
ity, further labeling or functionalization of
the surface is still feasible. Microparticles did
not induce changes in plasma cytokine con-
centrations after subcutaneous administra-
tion in rats.19 By combining the advanta-
geous properties of the PSi materials with
those of nanoscaled vehicles, even greater
benefits in the development of drug deliv-
ery carriers can be achieved.8 It is known
that silicon-based nanomaterials can de-
grade rapidly in vivo into orthosilicic acid
and therefore be easily excreted from the
animal body.8 However, limited attention
has been drawn to the toxicological profil-
ing of the PSi degradation products. The in-
herent luminescence of oxidized PSi materi-
als20 is advantageous when noninvasive
imaging is considered.8 Nonetheless, not
all modified PSi materials exhibit lumines-
cence and, therefore, alternative labeling
approaches need to be investigated to as-
sess their performance noninvasively in
vivo. The use of optical imaging techniques
is essentially limited to mice due to the lim-
ited light penetration depth, rendering
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ABSTRACT Porous silicon (PSi) particles have been studied for the effects they elicit in Caco-2 and RAW 264.7
macrophage cells in terms of toxicity, oxidative stress, and inflammatory response. The most suitable particles
were then functionalized with a novel 18F label to assess their biodistribution after enteral and parenteral
administration in a rat model. The results show that thermally hydrocarbonized porous silicon (THCPSi)
nanoparticles did not induce any significant toxicity, oxidative stress, or inflammatory response in Caco-2 and
RAW 264.7 macrophage cells. Fluorescently labeled nanoparticles were associated with the cells surface but were
not extensively internalized. Biodistribution studies in rats using novel 18F-labeled THCPSi nanoparticles
demonstrated that the particles passed intact through the gastrointestinal tract after oral administration and
were also not absorbed from a subcutaneous deposit. After intravenous administration, the particles were found
mainly in the liver and spleen, indicating rapid removal from the circulation. Overall, these silicon-based
nanosystems exhibit excellent in vivo stability, low cytotoxicity, and nonimmunogenic profiles, ideal for oral
drug delivery purposes.
KEYWORDS: porous silicon · nanoparticles · oral delivery · cytotoxicity ·
biodistribution · Caco-2 cells
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nuclear imaging the only method fully translational
from laboratory animals to humans.
When the potential of novel biomaterials or nano-
materials is considered, a systematic investigative ap-
proach is required to evaluate their potential hazard
upon administration.21 The particle size is a key element
to be taken into account, as the surface area of the par-
ticles in contact with the cell varies. For evaluation of
biocompatibility and suitability of THCPSi nanoparti-
cles for oral delivery applications, different particle sizes
were investigated. They were then tested with both
Caco-2 human colon carcinoma (an in vitro model for
the intestinal epithelium barrier) and RAW 264.7 mu-
rine macrophage cells (an in vitro model used for cellu-
lar uptake and inflammation studies), and their biodis-
tribution in rats was determined. Here we demonstrate
that the THCPSi nanoparticles have low toxicity, do not
elicit significant oxidative or inflammatory response,
and associate strongly with the cell membrane with-
out internalizing. Furthermore, radiolabeled THCPSi
nanoparticles pass intact through the gastrointestinal
tract and do not permeate the intestinal wall. From the
results drawn in this study, we conclude that THCPSi
nanoparticles are a safe and promising vehicle for oral
drug delivery applications.
RESULTS AND DISCUSSION
Production and Characterization of Porous Silicon Particles.
Porous Si films were synthesized by electrochemical etch-
ing the Si wafers with HF and ethanol. To perform the in
vitro and in vivo studies, we have prepared thermally
hydrocarbonized silicon (THCPSi) particles with several
sizes ranging from micro- to nanosize. The preparation
and physicochemical characterization of the PSi micro-
particles have been described in detail in the
literature.3,12,14,15,19,22 In this study, two microsized THCPSi
fractions were prepared: 110 and 1025 m. The aver-
age pore diameter of these particles was 9.8 nm. The spe-
cific surface area was 322 m2/g, and the pore volume
was 0.81 cm3/g. In the case of PSi nanoparticles, the frac-
tions prepared were 97, 142, and 188 nm. The average
pore diameter of the THCPSi nanoparticles was 9.0 nm.
The specific surface area was 202 m2/g, and the pore vol-
ume was 0.51 cm3/g. The measured zeta ()-potential of
the THCPSi nanoparticles was about30 mV.
After etching and drying, the PSi surfaces are un-
stable in aqueous solution due to oxidation of the reac-
tive surface hydrides, and therefore, a thermal hydro-
carbonization was used to improve its stability. The
particles obtained in this manner are stable and allow
further surface modifications with molecules such as
fluorescent labels or radioisotopes.
Figure 1a shows the transmission electron micro-
scope (TEM) pictures of THCPSi nanoparticles prepared
by the above-mentioned method. The particles showed
a very spherical-round shape with an average size of 142
nm. The surface of the THCPSi nanoparticles was further
modified with fluorescein isothiocyanate (FITC) for cell as-
sociation and uptake studies (Figure 1b). These particles
exhibited similar size as the 142 nm unlabeled THCPSi
(Figure 1a,b). In addition, the THCPSi nanoparticles were
also grafted with 18F for the in vivo studies (Figure 1c, see
Materials and Methods for details).
Figure 1. Transmission electron microscope (TEM) images of unla-
beled THCPSi (a), FITC-THCPSi labeled (b), and 18F-THCPSi labeled (c)
nanoparticles used in this study and their respective size distribution.
Scale bars are 500 nm. Measured potentials of THCPSi nanoparticles
(d) before labeling (squares) and after 18F-labeling (circles).
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The specific radioactivity of cyclotron-produced
[18F]fluoride is high, typically exceeding 5 Ci/mol (185
GBq/mol).23 In this study, 0.51.0 GBq of no-carrier
added [18F]fluoride corresponding to less than 0.1 g
in mass was used to label a 10000-fold excess of 1 mg
of THCPSi nanoparticles. Therefore, radiolabeling of the
THCPSi surface with a trace amount of 18F is unlikely to
result in detectable change in the particle size and sur-
face chemistry and, consequently, alterations in the in
vivo behavior of the nanoparticles. Most importantly, it
can be seen that the labeling of the THCPSi surface with
FITC or 18F did not affect the physicochemical proper-
ties of the particles. All the labeled particles were mor-
phologically similar to unlabeled THCPSi nanoparticles
in terms of size and shape (Figure 1ac), as well as in
terms of surface charge, as demonstrated by the nega-
tive -potential (Figure 1d). Furthermore, the lack of in-
fluence of 18F radiolabeling on the surface chemistry
was confirmed by the identical FTIR spectra of both un-
labeled and radiolabeled THCPSi free-standing films
(see Supporting Information, Figure 1).
In Vitro Toxicity, ROS Production, and Inflammatory Reaction.
We evaluated the in vitro cytotoxic, oxidative, and inflam-
matory responses in the above-mentioned cell lineswhen
exposed to the THCPSi particles for 24 h. PSi particles are
known to react in common colorimetric viability assays
such as the MTT24 or LDH, leading to false results. There-
fore, a validated luminescent method based on the quan-
tification of metabolically active (in terms of ATP con-
tent) cells was used.25 The THCPSi microparticles of size
fraction 110 m were found to be more cytotoxic than
all other particle sizes in the Caco-2 cell line, although the
1025mparticles exhibited also some toxicity at higher
concentrations (Figure 2a). THCPSi nanoparticles with an
average size of 97 and 188 nm reduced viability com-
pared to 142 nm particles in RAW 264.7 macrophages
(Figure 2b). The intracellular reactive oxygen species
(ROS) production, which is often used to evaluate nano-
particle toxicity21 was assessed using dichloro-
dihydrofluorescein diacetate (DCF-DA). This probe is non-
fluorescent unless oxidized by the intracellular ROS to
fluorescent DCF. The extent of oxidative response, evalu-
ated in terms of the intracellular ROS, was of the same or-
der of magnitude throughout all size ranges studied for
both cell cultures and significantly lower than for the posi-
tive control, H2O2 (Figure 2c,d). The THCPSi microparticle-
induced intracellular ROS production remained low de-
spite the lower viability values, which suggests that these
particles are interacting with the extracellular cell mem-
branes, resulting in cellular damage due to ATP depletion
without further production of ROS. Inflammatory re-
sponses were measured in terms of tumor necrosis fac-
tor  (TNF-) production. TNF- is a polypeptide cytok-
ine produced by macrophages that stimulates acute
phase reaction.26 The results demonstrated that THCPSi
nanoparticles with an average size of 142 and 188 nm
triggered a lower production of TNF- than the other in-
vestigated particles (Figure 2e). These results are in good
agreement with those shown in Figure 2ad.
It has been shown that particle size plays a crucial
role in determining cytotoxicity, as different pathways
and cellular processes are engaged and modulated upon
particle contact.27,28 Our results suggest that the most
toxic size fraction of THCPSi particles is 110 m, which
reduced the cell viability the most (Figure 2a,b). On the
other hand, the THCPSi particles of 142 nm interacted less
strongly with the cells, thus, inducing less cellular dam-
age and maintaining high levels of cellular ATP produc-
tion even after 24 h. These effects were both size and con-
centration dependent. It is already established that
particle size can strongly affect the efficiency of cellular
uptake28,29 and there seems to be a correlation between
several size ranges and a significant alteration in signaling
processes.27 The fact that different internalization path-
ways can occur even between particles of a narrow range
of sizes and also that due to the fact that most micro-
and nanoparticle dispersions are not completely homo-
geneous accounts for the possibility that minor fractions
in particle dispersions could be responsible for some of
the biological effects. These results illustrate the impor-
tance of a clear understanding and control of particle size
distribution in micro- and nanoparticle dispersions for
biological purposes. The route of internalization into the
cell, as well as the interaction with the cell wall, can exten-
sively modulate viability. Inorganic particles below 100
nmwere found to be internalized to a greater extent and
to reduce viability.25,27 However, it has also been sug-
gested that an inflection point on the particular internal-
ization route is apparent at a size of approximately 200
nm,28 which is also corroborated in our study. It is for that
reason that when designing a micro- or nanoparticulate
drug delivery system it is advisible to avoid the thresholds
that were found to have a greater impact on cell viabil-
ity. In RAW 264.7 macrophages, the oxidative and cyto-
toxic responses seem to be of a higher level when com-
pared to Caco-2 cells, which can be attributed to their role
in the inflammatory process in response to the particles.30
The cytotoxicity and oxidative stress induced by silicic
acid resulting from the complete dissolution of the TH-
CPSi particles was also investigated. Silicic acid from the
dissolved particles was noncytotoxic and did not elicit any
oxidative response in Caco-2 cells at concentrations up
to 100M (see Supporting Information, Figure 2, and also
details on the silicic acid determination).
In Vitro Cell Association. Because the THCPSi nanoparti-
cles of 142 nm revealed the most promising results in
both Caco-2 and RAW 264.7 macrophage cells, we pro-
ceeded to further characterize the in vitro cellular asso-
ciation of these nanoparticles in detail. For this purpose,
the Caco-2 and RAW 264.7 macrophage cells were incu-
bated with the FITC labeled THCPSi nanoparticles.
These particles showed a strong cellular association in
a concentration-dependent manner (Figure 3a,b).
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The extent of the particle internalization by the
cells was confirmed by confocal microscopy (Figure 3c)
and by analyzing the different focal planes acquired
through each sample (z-stacks). It was observed that
the majority of the particles remained attached to the
cell surface when compared to controls (Figure 3c). Fur-
thermore, permeability of FITC-labeled THCPSi nano-
particles across Caco-2 monolayers indicated that less
than 2% permeated across the Caco-2 monolayers in
4.5 h regardless of the particle concentration (Figure
3d). We postulate that the negative -potential of TH-
CPSi particles (Figure 1d) together with their hydropho-
bic nature favors a strong particlemembrane interac-
tion,31 but extensive internalization is prevented.32 The
strong membrane interaction due to the THCPSi hydro-
phobic nature could cause toxicity,31 an effect not ob-
served with our 142 nm THCPSi particles, which indi-
cates their high biocompatibility.
In Vivo Distribution. For evaluating the suitability of TH-
CPSi nanoparticle carriers for drug delivery applications,
it is necessary to gain detailed knowledge about their
biodistribution and behavior in vivo. The FITC-label is
quenched in acidic environments such as the stomach
and is, therefore, unsuitable for labeling particles in-
tended for oral administration. To overcome this prob-
lem and assess the biodistribution of THCPSi nanoparti-
cles in rats, we developed novel 18F-labeled THCPSi
nanoparticles. The 109.8 min half-life of 18F is long
enough to allow the follow-up of slower physiological
processes, such as passage in the gastrointestinal tract.
Furthermore, as 18F is a short-lived positron emitter, it
can be used for noninvasive visualization of particle dis-
tribution with positron emission tomography (PET), a
fully translational, highly sensitive, and quantitative mo-
lecular imaging method.
Radiolabeled 18F-THCPSi nanoparticles were admin-
istered to male Wistar rats using three different routes:
oral administration by intragastric gavage, subcutane-
ous and intravenous injections. Control animals re-
ceived 18F-NaF in the vehicle to establish the biodistri-
bution pattern of free [18F]fluoride in the experimental
setup. Administered doses are given in Table 1. The
[18F]fluoride ion is a known bone-seeking radiotracer,
showing high and rapid bone uptake in rats.33,34 In the
biodistribution studies with 18F-labeled radiopharma-
ceuticals, 18F accumulation in bone is commonly re-
garded as an indicator of the level of defluorination of
the tracer in vivo.33 Therefore, we administered to con-
trol animals [18F]F as sodium fluoride to differentiate
the 18F-labeled nanoparticles from detached free 18F-
label in the nanoparticle biodistribution study. The re-
sults showed that the nanoparticles did not cross the in-
testinal wall, as seen by the negligible amount of
radioactivity detected in the systemic circulation or or-
gans outside the gastrointestinal tract (Figure 4a,b).
The observed appearance of radioactivity in bone
and urine (0.6 ID%/g) at later time points was due tomi-
Figure 2. Cytotoxicity, oxidative stress, and inflammatory re-
sponses to THCPSi particles in Caco-2 and RAW 264.7macroph-
age cells. Cellular viability of Caco-2 (a) cells and RAW 264.7
macrophage (b) cells after 24 h incubation with different con-
centrations (g/mL) of THCPSi particles, assessed by a lumines-
cence assay. Intracellular ROS assessment of Caco-2 cells (c)
and RAW 264.7 macrophage (d) cells after 24 h incubation with
different concentrations (g/mL) of THCPSi particles, deter-
mined with fluorescent 2=,7=-dichlorodihydrofluorescein diace-
tate (DCF-DA). A cell-free assay was performed to assess the in-
terference of the particles in the fluorescence measured in
the ROS assay. There was no evidence of significant interfer-
ence from the particles. The negative control for ROS (cells
only) was found to yield a value of 6.6%  0.8. TNF- assess-
ment of RAW 264.7 macrophage (e) cells after 24 h incubation
with different concentrations of THCPSi particles. Error bars
represent mean  SEM (n > 3), except for TNF-, in which er-
ror bars represent s.d. for a given exposure group. Statistically
there is a significant difference between untreated (control)
cells incubated with buffer only (a, b, and e) or 0.09% H2O2 (c
and d); *P  0.05 and **P  0.01.
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nor detachment of the 18F-label, which can be caused by
the in vivo defluorination or disintegration of the particles
themselves. Distribution of the released radiolabel was
consistent with the behavior of free 18F observed in con-
trol animals after administration of 18F-NaF in the vehicle
(Figure 4c,d). Macroautoradiographical analysis of the
Figure 3. Particle association of FITC-labeled THCPSi nanoparticles in Caco-2 and RAW 264.7 macrophage cells. Caco-2 (a)
and RAW 264.7 macrophage (b) cells were incubated with THCPSi nanoparticles (15 and 50 g/mL) for 3 h. Untreated cells
(control) are shown for comparison. FITC-labeled THCPSi nanoparticles (green) associated with cells were detected by flow
cytometry. Mean fluorescence intensities (MFI) of FITC were measured and the values were normalized to the maximum ex-
tent of association in each cell line (n > 3; mean  SEM). Confocal microscopy images, with z-stack planes of Caco-2 mono-
layers and RAW264.7 macrophage (c) cells (scale bars 20 m) stained in orange, were incubated for 3 h with FITC-labeled
THCPSi nanoparticles (in green). The enlarged view represents a RAW 264.7 macrophage (scale bar 5 m). Permeation
of FITC-labeled THCPSi nanoparticles across Caco-2 cell monolayers (d) as a function of time (n> 3; mean SEM).
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lower gastrointestinal tract showed that the majority of
the administered nanoparticles reached the distal parts of
colon in 6 h and were excreted in fecal pellets (Figure
5a), but a more dispersed pattern was observed in con-
trol animals given 18F-NaF (Figure 5b). Some interindivid-
ual variation associated with the activities of the animal
(e.g., rest, drinking, coprophagy, and pica) during the
study period was observed in the rate at which the par-
ticles were excreted. In some animals, reappearance of ra-
dioactivity in the small intestinewas seen due to coproph-
agy (Figure 4b,d).
After intravenous administration into the lateral tail
vein (Figure 6a) the particles were found in the liver and
spleen, indicating that they are rapidly removed from
the circulation.8 The tail segment surrounding the injec-
tion site was removed after sacrifice and its radioactivity
counted to verify successful injection and lack of radioac-
tivity at the injection site (data not shown). THCPSi nano-
particles were administered subcutaneously under the
loose skin at the back of the animal. The particles resided
in the subcutaneous space for up to 4 h postinjection. This
was confirmed by qualitative post-mortem autoradiogra-
phy of the backside of the whole rat. The biodistribution
data for subcutaneous administration showed only mini-
mal leakage of dissociated 18F-label into the circulation
and subsequent accumulation in bone and urine (Figure
6b). As expected, significantly higher 18F bone uptake was
seen in control animals in all administration routes. In ad-
dition, free 18F was rapidly extracted into urine in large
amounts after intravenous and subcutaneous injections,
whereas in particle-dosed animals less than 1 ID%/g was
excreted via the kidneys (Figure 4a). In control animals
dosed orally, slightly slower kinetics of bone uptake were
observed compared to the parenteral routes (Figure 4c),
and macroautoradiography showed a dispersed distribu-
tion pattern, reflecting 18F absorption from the small in-
TABLE 1. AdministeredDoses of 18F-THCPSi and 18F-NaF in theBiodistribution Studies throughDifferentAdministrationRoutes
Intravenous Subcutaneous Oral
group particle(n8) control(n3) particle(n9) control(n6) particle(n9) control(n6)
THCPSi (mg) 0.030 0.011 0.075 0.044 0.214 0.069
A(MBq) 9.18 1.36 10.02 1.38 12.44 2.18 12.57 0.60 18.95 2.20 20.57 1.84
Figure 4. Biodistribution of 18F-labeled THCPSi nanoparticles after oral administration (a) and their radioactive distribution
in the lower GI tract (b), as quantified from autoradiography (n 34 at each time point; mean s.d.). Biodistribution of free
18F-NaF after oral administration in control animals (c) (n  2 at each time point; mean  s.d.) and its radioactive distribu-
tion in the lower GI tract in control animals after oral administration (d) quantified from autoradiography.
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testine as reported previously34 (Figure 5b). Biodistribu-
tion of free 18F-NaF (Figure 6c,d) showed a pattern clearly
distinguishable from that seen in particle-dosed animals
(Figure 6a,b), demonstrating excellent in vivo stability of
18F-THCPSi nanoparticles under different physiological
conditions.
CONCLUSION
The THCPSi particles have been shown to cause dif-
ferent cellular responses depending on the cell type
and route of administration, and therefore, particles
with well-defined sizes were investigated in this study.
The stability of THCPSi particles under the experimental
timeline investigated and the ease of labeling them
with fluorescent or radioactive labels for imaging pur-
poses render the material a flexible platform for func-
tionalization and further development in drug delivery
applications. However, while the stability of THCPSi par-
ticles is prospective for their oral delivery, demon-
strated biodegradability and favorable rate of degrada-
tion are critical for their subcutaneous administration
and still need to be investigated. In conclusion, this
study demonstrates for the first time the feasibility of
oral delivery of silicon-based nanoparticles by means of
in vitro cellular responses and interactions, as well as in
vivo biodistribution, stability, and safety. The results pre-
sented here constitute the first quantitative analysis of
the behavior of orally administered THCPSi nanoparti-
cles compared with other delivery routes in rats.
MATERIALS AND METHODS
Preparation of Thermally Hydrocarbonized Porous Silicon (THCPSi)
Particles. The free-standing porous silicon (PSi) films were anod-
ized using single crystal silicon wafers (100) of p-type with re-
sistivity values of 0.010.02 cm. The PSi was prepared by an-
odizing the wafers in an HF (38%)-ethanol mixture. The free-
standing films for microparticle production were etched for 40
min using a constant etching current (50 mA/cm2).
In the case of THCPSi nanoparticle production, the method
consisted of three different current pulses so that the first low
current pulse is used to produce a similar mesoporous silicon
structure as in the microparticles (porosity 	65%). The second
Figure 5. Macroautoradiographs and respective photographs of the GI tracts of rats 2, 4, and 6 h (from left to right) after
oral administration of 18F-labeled THCPSi nanoparticles (a) and free 18F-NaF (b). Abbreviations denote Duo, duodenum; Je, je-
junum; Ile, ileum; Ce, cecum; Asc, ascendens; Tra, transversum; and Des, descendens.
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pulse is shorter, with a high current pulse near the electropolish-
ing region, which produces highly porous andmechanically frag-
ile layers. The fragile layers predetermine the fracture sites on
the plane parallel to the surface of the porous film (see Support-
ing Information, Figure 3), while the pores determine them on
the perpendicular planes. A third zero-current pulse is then used
to remove the possible electrolyte concentration gradients in
the pores formed during the high current pulse, before the new
etching cycle starts. After drying, the pulse etched freestanding
films were thermally hydrocarbonized under a N2/acetylene (1:1)
flow at 500 °C for 10 min as described previously.3,19
The size reduction of the hydrocarbonized free-standing PSi
films (THCPSi) was done with ball milling. Wet milling was used
in nanoparticle production in order to increase the grinding effi-
cacy. Although the external surface of the milled nanoparticles
is mainly composed of the initial hydrocarbonized pore walls
(8090% of the external surface), we tried to reduce oxidation
of the new external surfaces created during the milling by using
1-decene as the milling liquid. The high grinding forces during
ball milling raise the temperature of the suspension locally at the
impact site, where it is high enough for a thermal hydrosilyla-
tion of aliphatic alkenes on the new surfaces35 but too low to oxi-
dize the hydrocarbonized surfaces. The surface chemistry of par-
ticles was verified with FTIR (data not shown) and by testing
the hydrophobicity of the nanoparticles. The final size separa-
tion and changes of the suspension media were done with
centrifugation.
The microparticles were produced with a short dry milling
of as-anodized free-standing films, after which the particles were
wet-sieved or filtrated to the desired size fractions and the sur-
face oxide was removed with a HF treatment prior to the hydro-
carbonization treatment similar to that used for nanoparticles.
Particle Characterization. The pore volume, average pore diam-
eter, and specific surface area of THCPSi micro- and nanoparti-
cles were calculated from desorption branch of nitrogen sorp-
tion (Tristar 3000, Micromeritics Inc.) measurements (results not
shown). Although the surface area and pore volume are reduced
in the nanoparticles, they are still sufficient considering drug de-
livery applications. The average nanoparticle sizes were mea-
sured from TEM (FEI Tecnai F12, Philips Electron Optics) images.
The samples for TEM were prepared by adding droplets of the
THCPSi nanoparticles (labeled and unlabeled) suspensions (pre-
pared in HBSS, pH	 7.4) on the coppercarbon grids and allow-
ing them to dry in a drybox for about 24 h. The size distribution
was then estimated using free ImageJ software. The microparti-
cle size was determined with laser diffraction (Mastersizer, Malv-
ern Instruments Ltd.) or with an automated optical microscopy
analysis (Morphologi G3, Malvern Instruments Ltd.).
18F-Radiolabeling of THCPSi Nanoparticles. All reagents and 1

HBSS buffer were purchased from Sigma-Aldrich, except for ab-
solute ethanol (Etax Aa,  99.7 vol-%, Altia Corporation) and
polyethylene glycol-15-hydroxystearate solubilizer (Solutol HS
15, BASF SE). Fluorine-18 was produced in a 18O(p,n)18F reaction
on a IBA Cyclone 5/10 cyclotron (Laboratory of Radiochemistry,
University of Helsinki, Helsinki, Finland). To 1 mg of THCPSi nano-
particles suspended in anhydrous DMF were added 500 L of
4% (v/v) acetic acid and 0.51 GBq of fluorine-18 as [18F]KF/
Kryptofix 2.2.2 in 100 L of DMF.36,37 The solution was heated at
120 °C for 15 min. Radiolabeled nanoparticles were purified with
sequential washes in absolute ethanol, ultrapure water, and 1

HBSS, pH	 7.4. Particles were centrifuged at 29000 g, the super-
natant was changed, and the particles were resuspended by son-
ication between washes. The final formulation was prepared in
5% Solutol-1
 HBSS (pH 	 7.4). Product specific radioactivity
was 207  139 MBq/mg at administration. The -potential mea-
surements were performed for each radiolabeled batch to verify
that the THCPSi surface chemistry was not affected by the label-
ing reaction.
Cell Culture and Toxicity. The in vitro studies with the THCPSi par-
ticles were performed with human colon carcinoma (Caco-2,
ATCC) and RAW 264.7 murine macrophage cells. Both cell lines
were obtained from American Type Culture Collection (ATCC).
The cells were cultured in 75 cm2 culture flasks (Corning Incorpo-
rated Life Sciences) using Dulbecco’s modified Eagle’s medium
(DMEM, Euroclone S.p.A) supplemented with 10% fetal bovine
serum (FBS, Gibco), 1% nonessential amino acids, 1%
Figure 6. Biodistribution of 18F-labeled THCPSi nanoparticles (a and b; n 24 at each time point; mean s.d.), and free
18F-fluoride in control animals (c and d) after intravenous (a and c) and subcutaneous (b and d) administration (n  12 at
each time point; mean s.d.).
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L-glutamine, penicillin (100 IU/mL), and streptomycin (100 g/
mL; all from Euroclone S.p.A.). The culture was maintained in a
BB 16 gas incubator at 37 °C (Heraeus Instruments GmbH) in an
atmosphere of 5% CO2 and 95% relative humidity. The growth
medium was changed every other day until the time of use. The
Caco-2 cells from passage numbers 3140 and RAW 264.7 mac-
rophages from passages 1720 were used in the experiments.
Prior to each test, the RAW 264.7 macrophages were harvested
using phosphate buffered saline (PBS)-ethylenediamine tet-
raacetic acid (EDTA) and Caco-2 cells were harvested using 0.25%
(v/v) trypsin-EDTA-PBS. For the toxicity assessment, 2 
 104
cells in DMEM were seeded in 96-well plates and allowed to at-
tach overnight. The medium was then aspirated, and 100 L of
THCPSi particle suspensions with concentrations of 250, 100, 50,
and 15 g/mL were added to the wells. After 24 h, 100 L of
the CellTiter-Glo reagent (Promega Corporation) was added to
each well according to the manufacturer’s instructions. In this as-
say the number of viable cells in culture is quantified based on
the amount of ATP produced by metabolically active cells. Thus,
the amount of ATP produced is directly proportional to the num-
ber of living cells presented in the culture. The plate was then
measured for luminescence using a Varioskan Flash fluorometer
(Thermo Fisher Scientific). All assays were made at least in tripli-
cate. The TNF- and ROS measurements were also made accord-
ing to manufacturer’s instructions.
Reactive Oxygen Species (ROS) Determination. The experiments
were performed as described elsewhere.4,38 Briefly, in 96-well
plates, 2 
 104 cells were seeded and allowed to attach over-
night. The medium was then aspirated, and afterward, 100 L
of 10 M 2=,7=-dichlorofluorescin diacetate (DCF-DA) solution
was added and allowed to incubate 1 h at 37 °C. The solution
was subsequently washed with HBSS and THCPSi suspension so-
lutions of concentrations of 250, 100, 50, and 15 g/mL were
added to the wells. Hydrogen peroxide treated cells (H2O2,
0.09%) was used as positive control. After treatment for 24 h,
the plate wells were washed and DCF fluorescence was mea-
sured in a Varioskan Flash (Thermo Fisher Scientific). Excitation
and emission wavelengths were 498 and 522 nm, respectively.
TNF- Assay. To assess TNF- production by the macroph-
ages, an enzyme-linked immunoabsorbent assay (ELISA) was
performed using a commercially available kit (Mouse TNF- 
ELISA, Bender MedSystems GmbH). First, serial dilutions of mu-
rine TNF- was prepared and pipetted into the 96-well plates
precoated with immobilized antibodies. Precollected superna-
tants from all the treated and control cells were then added to
the wells. After 2 h, the wells were washed and biotin-
conjugated specific for mouse TNF- was added to the wells.
The wells were then completely washed to remove any unbound
reactants after another 2 h. The amount of TNF- present in
each well was determined by measuring the absorbance for
each sample in a fluorometer at 450 nm. The amount of TNF-
produced by the RAW 264.7 macrophage cells was then calcu-
lated from the standard curve of known amounts of murine
TNF-. It should be emphasized that TNF- does bind to TH-
CPSi particles. Therefore, we have performed TNF- binding ex-
periments under the same conditions used during cell exposure
in order to evaluate the existing of binding and to further cor-
rect the results as described elsewhere.39
Flow Cytometry. In six-well plates (Corning Incorporated Life
Sciences), Caco-2 or RAW 264.7 macrophage suspensions were
seeded in every individual well and allowed to attach overnight.
Caco-2 and RAW 264.7 cells were incubated with 15 or 50 g/mL
of FITC-labeled THCPSi nanoparticle solutions for 3 h. After wash-
ing with HBSS, the cells in the wells were detached with trypsin-
EDTA. The cells were then carefully collected and centrifuged.
The final washing was performed with PBS-EDTA to prevent ag-
gregation of the cells. The cells were then fixed with 4%
paraformaldehyde (PFA, Fluka) in PBS for 20 min. The samples
were analyzed by a BD LSR II flow cytometer (BD Biosciences)
with a laser excitation wavelength of 488 nm, using FACSDiva
software. Exactly 10000 events were recorded. Untreated cells
were used as controls and the background (due to the particles
only) and debris were subtracted.
Caco-2 Permeability Experiments. Transport experiments were
performed in HBSS pH 7.4 at 37 °C using an orbital shaking (50
rpm). The Caco-2 cells were seeded on 12-Transwell cell culture
inserts (polycarbonate membranes, pore size 3 m, growth area
0.33 cm2, Corning Costar Corp). The cells were kept under the
same conditions as described in Cell Culture and Toxicity. Cells
were used in the experiments 2128 days after seeding. The
permeability of FITC-labeled THCPSi nanoparticles was studied
across Caco-2 cell monolayers in an apical-to-basolateral direc-
tion for 4.5 h. Control experiments (untreated cells) were per-
formed in parallel. The amount of FITC-labeled THCPSi nanopar-
ticles that had permeated across the Caco-2 monolayers was
then calculated from a standard curve of known FITC-labeled TH-
CPSi nanoparticles determined previously. The FITC-labeled
nanoparticles were stable under experimental conditions de-
scribed and no free FITC was detected during the study. The
monolayer integrity after each experiment was determined by
transepithelial electrical resistance and further assessed after the
permeability tests with [14C]mannitol (Amersham Biosciences).
Under the experimental conditions used, no damage to the
Caco-2 monolayers was observed (data not shown), which sup-
ports the cytotoxicity results in the study.
Confocal Microscopy. A solution of 1
 107 cells/mL was seeded
in 8-well chambered No. 1.0 borosilicate coverglass system
plates (Lab-Tek Nunc) and allowed to attach overnight. After
that, 30 or 100 g/mL of FITC-labeled THCPSi nanoparticles sus-
pensions were added to the wells for a final concentration of 15
and 50 g/mL and incubated for 3 h. The particles were then re-
moved and the wells washed three times with HBSS. CellMask
(Invitrogen) was added for cell staining according to manufac-
turer specifications. Prior to measurements, the cells were fixed
with 4% paraformaldehyde (PFA, Fluka) in PBS for 20 min. Con-
focal pictures were taken with a Leica SP2 inverted confocal mi-
croscope, equipped with argon (488 nm) and DPSS (561 nm) la-
sers, and using a HCX Plan Apochromat 63
/1.2 water
immersion objective (Leica Microsystems).
In vivo Biodistribution. All animal experiments were approved
by the National Committee for Animal Experimentation in Fin-
land (State Provincial Office of Southern Finland, Ha¨meenlinna).
The 18F-labeled THCPSi nanoparticles were administered to male
Wistar Han rats (age 710 weeks, University of Helsinki Labora-
tory Animal Centre) in 5% Solutol-1
 HBSS (pH 	 7.4) either by
intragastric gavage, subcutaneously on the back, or intrave-
nously via the lateral tail vein (n 	 89 for each administration
route). Control animals (n	 36 for each route) received 18F-NaF
in 5% Solutol-1
 HBSS. Animals were sacrificed at 2, 4, and 6 h,
or at 30 min, 1, and 4 h after administration for enteral and
parenteral routes, respectively.
Samples from blood, urine, mesenteric lymph node, liver,
lung, kidney, spleen, testis, brain, bone, and stomach were col-
lected. For intestinal biodistribution of radioactivity, the lower
gastrointestinal tract was excised and samples were taken from
duodenum, jejunum, ileum, cecum, and the ascending, trans-
verse, and descending parts of colon. Samples were weighed
and their radioactivity measured with a gamma counter (Wizard
3, PerkinElmer).
Macroautoradiography of the Lower Gastrointestinal Tract. For ani-
mals dosed by intragastric gavage, the whole lower gastrointes-
tinal tract was imaged with digital autoradiography prior to sam-
pling for radioactivity counting. The excised intestines were
arranged on a Fujifilm BAS SR2040 imaging plate together with
18F standards and photographed for macroanatomical identifica-
tion of different parts. Autoradiographs were analyzed with
AIDA 2.0 imaging software (Raytest Isotopenmessgera¨te GmbH).
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